AR021443A1 - Formulacion de liberacion controlada de divalproex sodio - Google Patents
Formulacion de liberacion controlada de divalproex sodioInfo
- Publication number
- AR021443A1 AR021443A1 ARP990106552A ARP990106552A AR021443A1 AR 021443 A1 AR021443 A1 AR 021443A1 AR P990106552 A ARP990106552 A AR P990106552A AR P990106552 A ARP990106552 A AR P990106552A AR 021443 A1 AR021443 A1 AR 021443A1
- Authority
- AR
- Argentina
- Prior art keywords
- weight
- tablets
- divalproex sodium
- formulation
- controlled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una formulacion de tableta de liberacion controlada que permite una dosificacion de una vez por día en el tratamiento de la epilepsia comprende dealrededor de 50% en peso a alrededor de 55% en peso de un ingrediente activo seleccionado del grupo queconsiste en ácido valproico, una sal o ésterfarmacéuticamente aceptable de ácido valproico, divalproex sodio y valpromida, alrededor de 20% en peso a alrededor de 40% en peso de hidroxipropil celulosa,de alrededor de 5% en peso a alrededor de 15% enpeso de lactosa, de alrededor de 4% en peso a alrededor de 6% en peso de celulosa microcristalina y dealrededor de 1% a alrededor de 5% en peso de dioxido de silicio con un tamano de partícula que va desde 1 micron hasta alrededor de 10 micrones, todos losporcentajes de peso basados en el peso total de la forma de dosificacion en tabletas. También se describen formulaciones granulares previas a las tabletas,métodos para crear las formulaciones granulares y las tabletas y un método para tratar laepilepsia que emplea las formulaciones de tabletas de liberacioncontrolada de la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/216,650 US6419953B1 (en) | 1998-12-18 | 1998-12-18 | Controlled release formulation of divalproex sodium |
| US12155799P | 1999-02-25 | 1999-02-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR021443A1 true AR021443A1 (es) | 2002-07-17 |
Family
ID=26819594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990106552A AR021443A1 (es) | 1998-12-18 | 1999-12-17 | Formulacion de liberacion controlada de divalproex sodio |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1140034B1 (es) |
| JP (1) | JP2003513882A (es) |
| KR (1) | KR20010101295A (es) |
| CN (1) | CN1335769A (es) |
| AR (1) | AR021443A1 (es) |
| AT (1) | ATE254907T1 (es) |
| AU (1) | AU2478900A (es) |
| BG (1) | BG105665A (es) |
| BR (1) | BR9916361A (es) |
| CA (1) | CA2330480C (es) |
| CO (1) | CO5160287A1 (es) |
| CZ (1) | CZ20012201A3 (es) |
| DE (1) | DE69913197T2 (es) |
| DK (1) | DK1140034T3 (es) |
| ES (1) | ES2212667T3 (es) |
| HK (1) | HK1043043B (es) |
| HU (1) | HUP0105463A3 (es) |
| IL (1) | IL143407A0 (es) |
| NO (1) | NO20012986L (es) |
| PL (1) | PL356899A1 (es) |
| PT (1) | PT1140034E (es) |
| SI (1) | SI20624A (es) |
| SK (1) | SK8252001A3 (es) |
| TW (1) | TW585788B (es) |
| WO (1) | WO2000037055A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6713086B2 (en) | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US20020025341A1 (en) * | 1998-12-18 | 2002-02-28 | Yihong Qiu | Controlled release formulation of divalproex sodium |
| US6528090B2 (en) | 1998-12-18 | 2003-03-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6419953B1 (en) | 1998-12-18 | 2002-07-16 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| US6511678B2 (en) | 1998-12-18 | 2003-01-28 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| WO2002051402A1 (en) * | 2000-12-22 | 2002-07-04 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
| IL158959A (en) | 2001-05-25 | 2010-06-30 | Cephalon Inc | Solid pharmaceutical formulations comprising modafinil |
| US7229644B2 (en) | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040005357A1 (en) * | 2002-07-03 | 2004-01-08 | Sherman Bernard Charles | Extended-release tablets comprising divalproex sodium |
| US20040048931A1 (en) | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| MXPA05009886A (es) * | 2003-03-14 | 2006-05-04 | Nirmal Mulye | Un proceso para preparar tabletas de liberacion constante. |
| HUP0301537A3 (en) * | 2003-06-03 | 2005-07-28 | Egis Gyogyszergyar Nyilvanosan | Deramcyclane fumarate tablets and process for producing them |
| US7713550B2 (en) | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
| WO2006025029A2 (en) * | 2004-08-31 | 2006-03-09 | Ranbaxy Laboratories Limited | Extended release composition of divalproex |
| EA200701591A1 (ru) * | 2005-01-26 | 2008-02-28 | Элан Фарма Интернэшнл Лимитед | Композиции с контролируемым высвобождением, содержащие антипсихотическое средство |
| US20070202164A1 (en) * | 2006-02-28 | 2007-08-30 | Hutchison Medipharma Enterprises Limited | Andrographis Extract Formulations |
| CN102421428B (zh) * | 2009-05-12 | 2014-01-29 | 株式会社爱茉莉太平洋 | 用于防止脱发或促进毛发生长的组合物 |
| WO2012121862A2 (en) * | 2011-02-17 | 2012-09-13 | University Of Florida Research Foundation | Valproic acid derivative compounds |
| CN102138911B (zh) * | 2011-03-28 | 2012-12-12 | 孙卫东 | 一种双丙戊酸钠缓释片及其制备方法 |
| CN102895201B (zh) * | 2011-07-26 | 2014-09-10 | 北大方正集团有限公司 | 丙戊酸半钠片剂及其制备方法 |
| CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
| CN105012264B (zh) * | 2014-04-16 | 2019-11-29 | 四川科瑞德制药股份有限公司 | 丙戊酸钠缓释片及其制备工艺和用途 |
| CN106389368B (zh) * | 2015-07-29 | 2021-11-12 | 四川科瑞德制药股份有限公司 | 一种丙戊酸钠缓释制剂及其制备工艺和用途 |
| CN105456218A (zh) * | 2015-12-07 | 2016-04-06 | 黑龙江省智诚医药科技有限公司 | 一种丙戊酸镁缓释片及其制备方法 |
| CN107028907B (zh) * | 2016-02-04 | 2021-05-14 | 成都康弘药业集团股份有限公司 | 一种双丙戊酸钠缓释片 |
| CN114681419A (zh) * | 2020-12-28 | 2022-07-01 | 湖南省湘中制药有限公司 | 一种丙戊酰胺缓释片的组合物及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169642A (en) * | 1988-06-24 | 1992-12-08 | Abbott Laboratories | Sustained-release drug dosage units |
| US5009897A (en) * | 1988-06-24 | 1991-04-23 | Abbott Laboratories | Pharmaceutical granules and tablets made therefrom |
| FR2643556B1 (fr) * | 1989-02-27 | 1993-03-05 | Sanofi Sa | Composition pharmaceutique a liberation prolongee d'acide valproique |
| IL96311A (en) * | 1989-12-01 | 1995-05-26 | Abbott Lab | Medications with delayed release |
| US5075114A (en) * | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
| TW224049B (es) * | 1991-12-31 | 1994-05-21 | Sunkyong Ind Ltd | |
| TW222585B (es) * | 1992-09-11 | 1994-04-21 | Hoechst Ag | |
| JP3552285B2 (ja) * | 1993-08-03 | 2004-08-11 | 三菱化学株式会社 | 経口コレステロール低下剤 |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| CA2216215A1 (en) * | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
-
1999
- 1999-12-09 HU HU0105463A patent/HUP0105463A3/hu unknown
- 1999-12-09 PT PT99968104T patent/PT1140034E/pt unknown
- 1999-12-09 KR KR1020017007649A patent/KR20010101295A/ko not_active Application Discontinuation
- 1999-12-09 EP EP99968104A patent/EP1140034B1/en not_active Expired - Lifetime
- 1999-12-09 DE DE69913197T patent/DE69913197T2/de not_active Expired - Lifetime
- 1999-12-09 CA CA002330480A patent/CA2330480C/en not_active Expired - Fee Related
- 1999-12-09 AT AT99968104T patent/ATE254907T1/de active
- 1999-12-09 ES ES99968104T patent/ES2212667T3/es not_active Expired - Lifetime
- 1999-12-09 SK SK825-2001A patent/SK8252001A3/sk unknown
- 1999-12-09 PL PL99356899A patent/PL356899A1/xx not_active Application Discontinuation
- 1999-12-09 DK DK99968104T patent/DK1140034T3/da active
- 1999-12-09 JP JP2000589166A patent/JP2003513882A/ja active Pending
- 1999-12-09 WO PCT/US1999/029204 patent/WO2000037055A1/en not_active Application Discontinuation
- 1999-12-09 IL IL14340799A patent/IL143407A0/xx unknown
- 1999-12-09 CN CN99814629A patent/CN1335769A/zh active Pending
- 1999-12-09 BR BR9916361-6A patent/BR9916361A/pt not_active Application Discontinuation
- 1999-12-09 AU AU24789/00A patent/AU2478900A/en not_active Abandoned
- 1999-12-09 CZ CZ20012201A patent/CZ20012201A3/cs unknown
- 1999-12-09 SI SI9920100A patent/SI20624A/sl not_active IP Right Cessation
- 1999-12-15 CO CO99078240A patent/CO5160287A1/es unknown
- 1999-12-17 AR ARP990106552A patent/AR021443A1/es not_active Application Discontinuation
- 1999-12-18 TW TW088122338A patent/TW585788B/zh not_active IP Right Cessation
-
2001
- 2001-06-15 NO NO20012986A patent/NO20012986L/no not_active Application Discontinuation
- 2001-07-03 BG BG105665A patent/BG105665A/bg unknown
-
2002
- 2002-03-28 HK HK02102407.1A patent/HK1043043B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2330480C (en) | 2002-05-21 |
| CO5160287A1 (es) | 2002-05-30 |
| NO20012986D0 (no) | 2001-06-15 |
| DK1140034T3 (da) | 2004-03-08 |
| DE69913197T2 (de) | 2004-09-02 |
| SI20624A (sl) | 2002-02-28 |
| ES2212667T3 (es) | 2004-07-16 |
| SK8252001A3 (en) | 2001-12-03 |
| HUP0105463A3 (en) | 2003-03-28 |
| CZ20012201A3 (cs) | 2001-09-12 |
| HUP0105463A2 (hu) | 2002-05-29 |
| NO20012986L (no) | 2001-08-15 |
| CN1335769A (zh) | 2002-02-13 |
| PT1140034E (pt) | 2004-03-31 |
| IL143407A0 (en) | 2002-04-21 |
| WO2000037055A1 (en) | 2000-06-29 |
| BR9916361A (pt) | 2002-11-05 |
| EP1140034A1 (en) | 2001-10-10 |
| BG105665A (bg) | 2002-03-29 |
| CA2330480A1 (en) | 2000-06-29 |
| ATE254907T1 (de) | 2003-12-15 |
| TW585788B (en) | 2004-05-01 |
| AU2478900A (en) | 2000-07-12 |
| KR20010101295A (ko) | 2001-11-14 |
| HK1043043B (zh) | 2004-09-10 |
| EP1140034B1 (en) | 2003-11-26 |
| DE69913197D1 (de) | 2004-01-08 |
| PL356899A1 (en) | 2004-07-12 |
| HK1043043A1 (en) | 2002-09-06 |
| JP2003513882A (ja) | 2003-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR021443A1 (es) | Formulacion de liberacion controlada de divalproex sodio | |
| AR028299A1 (es) | Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes. | |
| AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
| AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
| PT833618E (pt) | Forma farmaceutica solida para utilizacao oral | |
| DE69940557D1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| ES2331046T1 (es) | Formulacion de liberacion controlada. | |
| TW200630123A (en) | Oral medicinal product with modified release of at least one active principle in multimicrocapsular form | |
| ATE332138T1 (de) | Flibanserin zur behandlung extrapyramidaler bewegungsstörungen | |
| YU2494A (sh) | Farmaceutska formulacija za tretiranje zavisnosti od nikotina | |
| PT90466A (pt) | Processo de preparacao de composicoes farmaceuticas compreendendo um excipiente extragranular, higroscopio insoluvel em agua e um ingrediente activo, em particular a cimetidina | |
| ATE202926T1 (de) | Pharmazeutische brausepräparate enthaltend bioabbaubare mikrokapseln zur kontrolierten wirkstofffreisetzung | |
| PL295329A1 (en) | Method of improving oral administration applicability of a biological medication substance: dideoxypurin nucleoside | |
| AR030039A1 (es) | Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| AR025879A1 (es) | Granulaciones de celulosa hidrolizada de sales de farmacos | |
| Moen | Topical diclofenac solution | |
| ES2572180T3 (es) | Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada | |
| DE69803670D1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
| ES2057021T3 (es) | Un metodo de manufactura de una dosificacion farmaceutica solida en forma de triturado en tableta. | |
| PE20040040A1 (es) | Unidades de dosificacion de progestagenico | |
| ES2796055T3 (es) | Co-granulados de goma xantana y de goma acacia | |
| Struk et al. | Development of composition and technology of effervescent tablets with acetylsalicylic acid, paracetamol and caffeine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |